Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

Ver video

SenseDiabetes

Financiado

Cerrado

Diabetic neuropathy: a study on the effects of insulin resistance on its pathoph...

Diabetic neuropathy: a study on the effects of insulin resistance on its pathophysiology and a randomized clinical trial to prevent neural loss We are facing a global epidemic of type 2 diabetes (T2D). Diabetic neuropathy (DN) is the most common complication of T2D affecting ~50% of patients with T2D. If not diagnosed early, DN may lead to further catastrophic complicatio... ver más

01/09/2026

UOA

Presupuesto desconocido

Líder del proyecto

ETHNIKO KAI KAPODISTRIAKO PANEPISTIMIO ATHINO... No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Fecha límite participación Sin fecha límite de participación.

Financiación concedida El organismo HORIZON EUROPE notifico la concesión del proyecto el día 2024-09-02

HORIZON-WIDERA-2023-TALENTS-02-01: ERA Fellowships ExpectedOutcome:This action builds on the MSCA Postdoctoral Fellowships 2023 action (HORIZON-MSCA-PF...

I+D

Cerrada hace 1 año

0% 100%

Información adicional privada

No hay información privada compartida para este proyecto. Habla con el coordinador.

Participantes

UOA

Lider

Proyectos interesantes

TRANSLATIONAL

Medical Technol...

Data Science

2M€ Cerrado

BFU2011-24679

Medical Technol...

Data Science

115K€ Cerrado

DALI

Medical Technol...

Data Science

4M€ Cerrado

AGL2016-75329-R

Medical Technol...

Data Science

236K€ Cerrado

COMPAR-EU

Medical Technol...

Data Science

6M€ Cerrado

INNODIA

Medical Technol...

Data Science

42M€ Cerrado

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Duración del proyecto: 23 meses Fecha Inicio: 2024-09-02
Fecha Fin: 2026-09-01

Líder del proyecto

ETHNIKO KAI KAPODISTRIAKO PANEPISTIMIO ATHINO... No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Fecha límite de participación Sin fecha límite de participación.

Descripción del proyecto We are facing a global epidemic of type 2 diabetes (T2D). Diabetic neuropathy (DN) is the most common complication of T2D affecting ~50% of patients with T2D. If not diagnosed early, DN may lead to further catastrophic complications. However, despite its potentially huge impact on patients’ quality of life, and burden imposed on healthcare systems, patients with T2D and practitioners are often unaware of the manifestations of DN. To make things worse, currently there are no approved treatments for DN. SenseDiabetes has several aims. First, we wish to increase our knowledge regarding the pathophysiology of DN, specifically assessing whether patients with T2D and DN have worse insulin resistance compared to patients with T2D without DN. While previous studies on DN have shown an effect of insulin resistance on DN, poor indexes of insulin resistance have been used. In SenseDiabetes we will use for the first time the gold standard method for the assessment of insulin resistance, i.e. the euglycemic insulin clamp. Second, we will assess the efficacy of two commonly used antidiabetic drugs in early DN. Patients with T2D and early signs of DN will be randomized to receive treatment for 9 months with either Semaglutide or Empagliflozin. The effects of these drugs on DN outcomes (small fiber density, cardiovascular autonomic function) and advanced glycation end-products will be assessed. Further, we will study with ex vivo experiments the effects of the two drugs of peripheral nerve density (obtained with skin biopsies), and in in vitro experiments we will study the exact mechanisms of action of Semaglutide on cultures of peripheral nerves. Along with the scientific part, SenseDiabetes has a dedicated WP to increase awareness of DN.SenseDiabetes may thus be pivotal for the development of new strategies to combat DN. Also, SenseDiabetes aims to promote awareness of DN and thus increase societal impact through early recognition of DN and prevention of further complications.

Conecta tu I+D

Entra hoy

¿Olvidé mi contraseña?

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores